wijzerplaat schreef op 13 november 2020 15:07:
ir.arrowheadpharma.com/node/15816/pdfArrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of
Alpha-1 Liver DiseaseNovember 13, 2020- Serum Z-AAT reductions of 86-93%
- All patients demonstrated greater than 80% reduction in liver Z-AAT monomer
- 3 of 4 patients had a decrease in liver globule involvement
- 3 of 4 patients demonstrated reductions in Z-AAT polymer with a range of 68-97%
- All patients showed ALT reductions ranging from 36-66%